Jason Harris

March 17, 2021

PARP inhibitors and novel combinations targeting the androgen receptor will help define the future treatment paradigm for patients with metastatic castration-resistant prostate cancer.

February 26, 2021

Up to 50% of patients with B-cell malignancies will relapse on CAR T-cell therapy. Investigators are looking in to new ways to overcome that drug resistance.

November 12, 2020

An immunologist and oncologist, Merad has spent her career studying inflammation in patients with cancer and was at the right place at the right time to translate her expertise to examine inflammation in patients with COVID-19.

October 10, 2020

Maintaining sexual function is often low on the list of priorities for a woman recently diagnosed with a gynecologic cancer, but raising the subject early in her treatment course may make the patient more willing to engage in a discussion as her care progresses, according to Don S. Dizon, MD, who specializes in survivorship issues.

June 13, 2020

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.

April 28, 2020

Treatment with talazoparib (Talzenna) did not demonstrate a statistically significant overall survival (OS) benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer, according to updated findings from the phase 3 EMBRACA trial (NCT01945775).1 However, lead author Jennifer Litton, MD, said that there is still reason to believe treatment with the PARP inhibitor can improve OS.

January 10, 2019

Waun Ki Hong, MD, a pioneering medical oncologist recognized for his practice-changing research in head and neck cancer, died at his home in California on January 2.

November 28, 2018

Rapid changes in the treatment landscape for melanoma have prompted the Society for Immunotherapy of Cancer (SITC) to issue updated consensus guidelines to help clinicians stratify patients, choose optimal treatment regimens, and manage immune-related adverse events (irAEs) in patients with stage II to IV disease.

October 04, 2018

Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

September 25, 2018

Safety and efficacy findings for regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (mCRC) were consistent with previous phase III results, according to findings from the phase IIIb CONSIGN trial.